The Role of Specific Mitogen-Activated Protein Kinase Signaling Cascades in the Regulation of Steroidogenesis by Manna, Pulak R. & Stocco, Douglas M.
Hindawi Publishing Corporation
Journal of Signal Transduction
Volume 2011, Article ID 821615, 13 pages
doi:10.1155/2011/821615
Review Article
TheRole of Speciﬁc Mitogen-ActivatedProtein Kinase
SignalingCascadesin theRegulation ofSteroidogenesis
PulakR.Manna and DouglasM. Stocco
Department of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA
Correspondence should be addressed to Douglas M. Stocco, doug.stocco@ttuhsc.edu
Received 3 September 2010; Accepted 28 November 2010
Academic Editor: M. Gaestel
Copyright © 2011 P. R. Manna and D. M. Stocco. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Mitogen-activated protein kinases (MAPKs) comprise a family of serine/threonine kinases that are activated by a large variety
of extracellular stimuli and play integral roles in controlling many cellular processes, from the cell surface to the nucleus. The
MAPK family includes four distinct MAPK cascades, that is, extracellular signal-regulated kinase 1/2 (ERK1/2), p38 MAPK, c-
Jun N-terminal kinase or stress-activated protein kinase, and ERK5. These MAPKs are essentially operated through three-tiered
consecutive phosphorylation events catalyzed by a MAPK kinase kinase, a MAPK kinase, and a MAPK. MAPKs lie in protein
kinase cascades. The MAPK signaling pathways have been demonstrated to be associated with events regulating the expression of
the steroidogenic acute regulatory protein (StAR) and steroidogenesis in steroidogenic tissues. However, it has become clear that
the regulation of MAPK-dependent StAR expression and steroid synthesis is a complex process and is context dependent. This
paper summarizes the current level of understanding concerning the roles of the MAPK signaling cascades in the regulation of
StAR expression and steroidogenesis in diﬀerent steroidogenic cell models.
1.Introduction
For the control of diverse signaling in response to the
extracellular milieu, cells develop sophisticated tools to
transmit the appropriate signals and thereby orchestrate the
responses. The signaling mechanism of an agent involves
eﬀector-receptor coupling, production of second messen-
gers, activation of protein kinases, and distribution of
these transducers to speciﬁc intracellular targets. Mitogen-
activated protein kinases (MAPKs) are the serine/threonine
kinase family of conserved enzymes that are considered
to be the central building blocks in the intracellular sig-
naling networks [1–5]. There are more than a dozen of
MAPKs known in mammals, and these enzymes exist in
several isoforms (Table 1). Mammals express four distinctly
regulated groups of MAPKs, that is, extracellular signal-
regulated kinase 1/2 (ERK1/2), p38, c-Jun N-terminal
kinases/stress-activated protein kinases (JNK/SAPKs), and
ERK5/BigMAPK(BMK1)[2,3,6].EachofthesefourMAPK
cascades consist of at least three tiers of protein kinases
that are consecutively activated by phosphorylation events:
MAPK kinase kinase (MAPKKK or MAP3K or MEKK) acti-
v a t e sM A P Kk i n a s e( M A P K K( M K Ko rM E K )o rM A P 2 K ) ,
which in turn activates MAPK. The latter phosphorylates a
large array of substrates, including MAPK-activating protein
kinases (MAPKAPKs) [7–9]. Even so, the diﬀerent tiers are
composed of many similar isoforms that can be activated
by more than one MAPK, increasing the complexity and
diversity of MAPK signaling. Substrates, regulation, and
function of diﬀerent MAPKs have been discussed in many
review articles [1, 2, 4, 5, 9–11], and will not be elaborated
upon in great detail here. MAPKs are important signal
transducingenzymesthatareinvolvedintransmitting signals
froma widevariety ofextracellularstimuliincludingthose of
growthfactors, hormones, cytokines,and neurotransmitters.
In fact, MAPKs are major components of signaling pathways
regulating a large array of intracellular events, such as pro-
liferation, diﬀerentiation, development, acute signaling in
response to hormones, stress response, programmed cell
death, gene expression, and steroidogenesis [1, 2, 12–14].
Noteworthy, however, the role of the MAPK signaling
pathways in steroidogenesis is poorly understood as a2 Journal of Signal Transduction
Table 1: MammalianMAP kinases.
MAP kinase Other names Relevant information Phosphorylationsite
motif
ERK1 P44 MAPK
∼86% sequence similarity to ERK2,
ubiquitously expressed, UO126 sensitive TEY
ERK2 P42 MAPK Ubiquitously expressed, UO126 sensitive TEY
ERK3 P63, ERKα Yields a single protein of 100kDa possessing
a C-terminal extension SEG
ERK1b ERK4 A separate gene TEY
JNK1 SAPKγ Several splice variants TPY
JNK2 SAPKα Several splice variants TYP
JNK3 SAPKβ Several splice variants TYP
P38α P38, CSBP, SAPK2,
MAPK14 Sensitive to SB203580 TGY
P38β P38-2, MAPK11 Sensitive to SB203580 TGY
P38γ ERK6, SAPK3, MAPK12 SB203580 insensitive TGY
P38δ SAPK4 or MAPK13 SB203580 insensitive TGY
Mxi2 A splice form of P38α TGY
Exip A splice form of P38α TGY
ERK5 BMK1 Cell proliferation, diﬀerentiation TEY
ERK7 MAPK15 Cell proliferation TEY
NLK Nemo-like kinase Ortholog of C. elegans LIT-1, relative of
Drosophila nemo TQE
MAK Male germ cell- associated
kinase
Expressed in testicular cells undergoing
meiosis TDY
MRK MAK-related kinase Ubiquitous in adult tissues TDY
MOK Phorbol ester sensitive TEY
KKIALRE Cdc2-related kinase TDY
KKIAMRE T, Y mutants activated in cells TDY
consequence of conﬂicting reports demonstrating stimula-
tion, inhibition, or no eﬀect in diﬀerent steroidogenic cells
[12, 15–18].
The steroidogenic acute regulatory protein (StAR) medi-
ates the rate-limiting and regulated step in steroid hormone
biosynthesis, that is, the transfer of the substrate for all
steroid hormones, cholesterol, from the outer to the inner
mitochondrial membrane [19–25]. As such, this protein
plays a crucial role in the regulation of steroid hormones
required for life itself, in the case of adrenal steroids, and
for maintaining normal reproductive function, in the case
of gonadal steroids. StAR is a rapidly synthesized, labile
phosphoprotein,whose expression,activation andextinction
are regulated by PKA, PKC, and a host of other signaling
pathways (reviewed in [23, 25–27]). The StAR protein is
localized to the mitochondria and consists of several forms
of a newly synthesized 30-kDa protein, which has a 37kDa
precursor form containing an N-terminal mitochondrial
targetingsequence[28,29].StARisprimarilyassociated with
steroid producing tissues, and studies have demonstrated
a tight correlation between the synthesis of StAR proteins
and the synthesis of steroids. The compelling evidence for
the critical role StAR in the regulation of steroidogenesis
has been illustrated by the targeted disruption of the StAR
g e n ea n db yt h es t u d yo fp a t i e n t ss u ﬀering from lipoid
congenital adrenal hyperplasia, in which both adrenal and
gonadal steroid biosyntheses are severely impaired due
to mutations in the StAR gene [30–33]. In the adrenal
and gonads, cAMP mediated mechanisms predominantly
regulate expression of the StAR protein and steroid synthesis
that involve transcriptional and translational induction.
Conversely, transcriptional and/or translational inhibition of
StAR expression results in a dramatic decrease in steroid
biosynthesis, with the exception of approximately 10%–
15% of steroid production that appears to occur through
StAR-independent events [34–38]. It should be noted that
phosphorylation of StAR is required to produce optimal
cholesterol transferring ability of the StAR protein in steroid
biosynthesis. Two putative PKA phosphorylation sites at
serine 56/57 and serine194/195 have been identiﬁed, in
murineandhumanStARrespectively,andmutationsinthese
sites demonstrated the functional importance of the latter in
thebiologicalactivityofStAR[39,40].WhilethecAMP/PKA
pathway is unquestionably the major signaling pathway for
trophic hormone-stimulated StAR expression and steroid
biosynthesis, it has been well established that the MAPK
signaling cascades play important roles in regulating these
processes. The purpose of this paper is to summarize the
ﬁndings ofa number oflaboratories,includingourown, that
have examined the roles of four distinct mammalian MAPKJournal of Signal Transduction 3
cascades in regulating steroidogenesis, and where evidence
exists, on StAR expression, in steroidogenic cells.
2.The MAPKSignaling Cascade
The MAPK signaling cascade involves activations of several
transmembrane signaling molecules, cytoplasmic protein
kinases, and a network of interacting proteins, and these, in
turn, regulate almost all cellular processes, from geneexpres-
sion to cell death [1, 3, 7, 14, 41, 42]. Each of these cascades
consists of several tiers of protein kinases that sequentially
activate each other upon phosphorylation. Activation of
each of the MAPK pathways is mediated by small GTP-
b i n d i n gp r o t e i n s( e . g . ,R a s ,R a p ,o ro t h e ro n c o p r o t e i n s ) ,
or by scaﬀold proteins or by adaptor molecules [41, 43,
44]. These events allow the transmission of extracellular
signals to appropriate intracellular targets either directly or
through three-tiered kinase modules [8, 10, 41]. MAPKs
are activated by phosphorylation cascades that contain at
least two upstream protein kinases. In all MAPK cascades,
the kinase immediately upstreaming of the MAP kinase
is a member of the MAP/ERK kinase (MEK or MKK)
family. These are dual-speciﬁcity enzymes that are capable
of phosphorylating serine/threonine and tyrosine residues
in their MAP kinase substrates in order to activate the
protein’s activity [8, 45–47]. However, it is known that
MAP kinases have overlapping substrate speciﬁcities. The
MEKs are also activated by phosphorylation on serine or
threonine residues in theiractivation loops. There are several
and diverse MEK kinases (MEKKs) that activate MEKs
[4, 9] .I nc o n t r a s t ,t h ea c t i v i t yo fM A P K si sn e g a t i v e l y
regulated byMAPK phosphatases, agroupof dual-speciﬁcity
phosphatases that remove phosphate from serine/threonine
or tyrosine residues and thereby inactivate MAPKs for
controlling signals [48–50].
The MAPK signaling pathway has long been implicated
in the regulation of cell cycle progression, is used as a
biochemical marker in evaluating the mitogenic eﬀects of
a variety of stimuli, and is a point of convergence for
diverse signaling pathways [12, 15, 16, 51, 52]. In mammals,
four distinct MAPK cascades (ERK1/2, p38, JNK/SAPK, and
ERK5/BMK1) are primarily activated by speciﬁc MAPKKs,
that is, MEK1 and MEK2 for ERK1/2, MKK3/6 for p38,
MKK4/7 for JNK/SAPK, and MEK5 for ERK5/BMK1 [1,
2, 41]. Nevertheless, each MAPKK can be induced by
many MAPKKKs, and presumably each MAPKKK confers
responsiveness to discrete signals [9, 53]. The diﬀerential
expression, activation, and substrate speciﬁcity of these
MAPKs suggest their varying physiological functions in
diﬀerent cellular contexts. A substantial body of evidence
indicates that MAPK signaling cascades are activated by a
large number of extracellular signals and play pivotal roles
in regulating the steroidogenic response. As such, a variety
of exogenous stimuli (e.g., hormones, growth factors, and
cytokines) that inﬂuence diﬀerent MAPK cascades exhibit
diverse eﬀects on StAR expression and steroidogenesis in
diﬀerent steroidogenic cell models (Figure 1;[ 12, 15–17, 54,
55]).
2.1. ERK1/2 Signaling and Its Role in StAR Expression and
Steroidogenesis. The ERK1/2 signaling cascade is the most
widely studied member of the MAPKs. ERK1 (p44 MAPK)
and ERK2 (p42 MAPK) are highly conserved throughout
eukaryoticcells and bringtogethertransmembrane receptors
and a network of various proteins and integrating signals
to control many cellular processes, including cell survival,
diﬀerentiation, tumor progression, and invasion [4, 7, 56–
58]. There are also alternatively spliced forms of ERKs,
namely, ERK1b (46kDa), ERK1c (42kDa), and ERK2b
(41kDa).ERKs are ubiquitouslyexpressed tovarying extents
in diﬀerent tissues. Both ERK1 and ERK2 are activated by
numerous extracellular stimuli, including growth factors,
cytokines, transforming agents, and ligands that act via
G protein-coupled receptors (GPCRs) and tyrosine kinase
receptors. The two phosphoacceptor sites, tyrosine and
threonine, in the activation loop (TEY) are phosphorylated
in order to activate the ERK1/2 signaling cascade, which
occurs exclusively through MEK1 and MEK2. ERKs also
phosphorylate several substrates (e.g., ribosomal S6 kinase
(RSK), the MAPK/SAPK-activated kinase (MSK)) either in
the cytosol (e.g., PLA2) or in the nucleus (e.g., Elk1) [1, 4, 9,
11]. However, this activation requires adaptor proteins that
are linked to the guanine exchange factors (GEFs) of GTP-
binding proteins. Following stimulation, recruitment of the
adaptor protein-GEF complex to the plasma membrane
results in the induction of Ras or related molecules, which
then transmit signals to the MAP3K level of the cascade
(Raf-1, B-Raf, A-Raf, TLP-2, and MEKK1) [1, 9, 59]. This,
however, is an oversimpliﬁcation of the ERK1/2 signaling
module. Generally, the three-tiered system of the ERK1/2
signaling cascade is rather complex and involves many
MEKKs that are capable of phosphorylating a number of
MEKs and thereby activating several MAP kinases and have
been discussed elsewhere [1, 2, 4, 11, 41].
The involvement of the ERK1/2 pathway in steroido-
genesis has been widely studied. This signaling pathway is
involved in regulating StAR expression and steroid biosyn-
thesis, butseveralseemingcontradictionshavebeenreported
in diﬀerent steroidogenic tissues [12, 15–17, 54, 60–62]. For
example, it has been demonstrated that activation ofERK1/2
by hCG increases StAR expression and testosterone produc-
tionwhileinhibitionofERK1/2byU0126resultsindecreases
in these parameters in hCG-stimulated primary cultures
of immature rat Leydig cells [61]. In contrast, ERK1/2
inhibition enhances StAR expression as induced by LH,
insulin-like growth factor-1 (IGF-1), transforming growth
factor-α, and interleukin-1α (IL-1α) but decreases steroid
levels [2, 12, 52, 62, 63]. It has been reported that steroid
biosynthesis induced by hCG and ﬁbroblast growth factor-
9 (FGF-9) is mediated through the involvement of Ras-
MAPK and PKA signaling in mouse Leydig cells [64, 65]. We
have demonstrated that the ERK1/2 signaling cascade plays
key roles in PKA-mediated (activated by (Bu)2cAMP and
hCG)- and PKC-mediated (activated by PMA) regulation of
steroidogenesis [12, 52,66].All these agentsactivate ERK1/2;
however, they have diverse eﬀects on StAR expression
and steroid synthesis in conjunction with ERK1/2 inhibi-
tion by either PD98059 or U0126. In particular, whereas4 Journal of Signal Transduction
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Figure 1: A schematic model illustrating the involvement of multiple signaling in MAPK-mediated regulation of StAR expression and
steroidogenesis. Interaction of trophic hormones with their speciﬁc membrane receptors results in the activation of G proteins (G), which,
in turn, stimulate adenylate cyclase (AC) that catalyzes the production of cAMP from ATP. cAMP then activates PKA and results in
the phosphorylation of transcription factors involved in StAR gene transcription. The binding of growth factors results in activation of
receptor tyrosine kinase and mediates biological functions via a number of mechanisms, including receptor autophosphorylation, receptor
clustering, and phosphorylation of intracellular proteins. This leads to the activation of a cascade of protein kinases including Ras/Raf,
and other related kinases. These protein kinases, in turn, activate diﬀerent transcription factors, including CREB/ATF-1, cFos, and cJun.
Phosphorylation of these transcription factors results in the transcriptional regulation of the StAR gene and, thus, steroid biosynthesis.
The PKA and PKC signalingpathways can directly or indirectly activate transcription factors, and both of these pathways are involved in the
MAPKmediated regulationofsteroidogenesis.Furthermore,cAMPand/ordiﬀerentfactors arealsocapableofactivatingacascadeofprotein
kinases (Rap/Ras/Raf or other related oncoproteins) leading to a number of MAPK signaling cascades, which have been demonstrated to
play important roles in regulating StAR expression and steroid biosynthesis in steroidogenic tissues.
the inhibition of ERK1/2 increases cAMP/hCG-stimulated
StAR expression, it decreases PMA-mediated StAR levels.
Nonetheless,progesteronelevelswerediminished inallcases.
The decrease in steroid synthesis was not associated with
attenuation of the cytochrome P450 side chain cleavage
(P450scc) and 3β-hydroxysteroid dehydrogenase (3β-HSD)
enzymeactivities,asERK1/2inhibitionhadnoeﬀecton22R-
hydroxycholesterol-mediated steroid synthesis [12]. Note-
worth y ,theincreasesinPMA,(Bu) 2cAMP,andhCG-induced
StAR expression and progesterone levels were inversely
correlated with the levels of a negative transcription factor,
namely, dosage-sensitive sex reversal, adrenal hypoplasia
congenita, critical region on the X-chromosome, gene 1
(DAX-1) [12, 52, 66, 67]. While U0126 attenuates DAX-1
expression, this inhibition can be reversed by PMA but not
by (Bu)2cAMP/hCG [12, 66]. In fact, the diﬀerential eﬀects
of U0126 on PKA- and PKC-mediated steroidogenesis is
mediated, at least in part, by alterations in DAX-1 expression
in mouse Leydig cells. Furthermore, studies have shown that
both(Bu)2cAMPandPMAcanelevatethelevelsofscavenger
receptor class B type 1 (SR-B1, a high-density lipoprotein
(HDL) receptor that binds various lipoprotein particlesJournal of Signal Transduction 5
and facilitates cellular cholesterol inﬂux) and that ERK1/2
inhibition decreases SR-B1 expression [12]. The binding of
HDL to SR-B1 has been reported to stimulate the ERK1/2
pathway following Ras activation [68]. SR-BI is involved
in importing cholesterol into cells that will eventually be
provided to the mitochondria for steroid biosynthesis [52,
69]. Thus it is plausible that the decrease in steroid synthesis
caused by U0126(during conditions of elevatedStAR)is due
to a reduction in cholesterol availabilityto the mitochondria.
Recent studies have shown that activation of ERK1/2 at
the mitochondria plays an important role in Leydig cell
steroidogenesis [70, 71]. Speciﬁcally, ERK1/2 is capable
of phosphorylating StAR at serine 232 in the presence
of cholesterol, demonstrating that StAR is a substrate for
ERK1/2 and that a mitochondrial kinase complex is essential
for maximum cholesterol transferring capacity of the StAR
protein in steroid synthesis.
In granulosa cell-derived rLHR-4 and rFSHR-17 cell
lines, treatments with LH/hCG and FSH, respectively, in-
crease ERK1/2 phosphorylation, StAR expression, and
progesterone synthesis [16, 17, 51, 72]. Conversely,
gonadotropin-stimulated StAR and steroid levels have
been shown to be further augmented following inhibition
of ERK1/2 both by PD98059 and U0126, suggesting that the
induction of LH/hCG- and FSH-induced steroidogenesis
involves downregulation of the steroidogenic machinery
including the ERK1/2 cascade. Studies have also shown that
while PD98059 and U0126 have no eﬀects on LH/hCG,
insulin, or IGF-1-induced steroidogenesis, they decrease
(Bu)2cAMP, cholera toxin and forskolin stimulated progest-
erone production [54, 60]. Further, it has been reported
that FGF-8 mediated ERK1/2 activity is associated with an
attenuation of estradiol production in rat granulosa cells
[73]. Also, ERK1/2 activation results in diﬀerential eﬀects
on LH-induced StAR and Cyp17 expression in bovine theca
cells. Activation results in an increase in StAR and a decrease
in Cyp17 that in turn results in an elevation in progesterone
and a reduction in androsterone levels, processes in which
DAX-1 and steroidogenic factor 1 (SF-1) play pivotal roles
[17]. Likewise, administration of hCG in vivo or treatment
with gonadotropins/cAMP in vitro is associated with
down-regulation of Cyp19a1 and upregulation of StAR and
Cyp11a1 mRNA expression in both mural and cumulus
granulosa cells of mouse preovulatory follicles [74]. These
events have been shown to be tightly regulated with steroid
biosynthesis and involve ERK1/2-dependent signaling.
Recently, the activation of ERK1/2, as well as other MAPK
signaling, by leptin, has been linked to decreases in basal and
cAMP/PKA stimulated StAR expression and progesterone
synthesis without aﬀecting the levels of the P450scc and
3β-HSD enzymes [75]. Additionally, treatment with met-
formin (a drug that is widely used for treating infertility
in women with polycystic ovary syndrome (PCOS)) causes
an activation of ERK1/2 that results in suppression of
insulin-stimulated P450 aromatase mRNA expression and
activity [76]. In theca cells isolated from PCOS patients,
increases in Cyp17 expression and androgen biosynthesis
are connected to an attenuation of ERK1/2/MEK1/2 activity
by PD98059, suggesting the involvement of MAPK signaling
in the pathogenesis of this disease [77]. Prostaglandin F2α
(PGF2α), an agent that inﬂuences luteal regression through
the induction of the phospholipase C/diacylglycerol/PKC
pathway, induces phosphorylation of ERK1/2, which, in
contrast, decreases basal and LH/hCG-stimulated StAR
expression and progesterone synthesis in human granulosa-
luteal cells [78]. These eﬀects of PGF2α in the steroidogenic
response can be reversed following inhibition of MEK
activity by PD98059. Moreover, the inhibitory eﬀect of
PGF2α on StAR expression and steroidogenesis, in rat luteal
cells, is modulated by the negatively acting transcription
factors, DAX-1 and ying yang 1 [18, 79]. These results
demonstrate the multiple eﬀects of the ERK1/2 signaling
cascade in StAR expression and steroidogenesis in gonadal
cells.
In mouse Y-1 adrenocortical tumor cells the induction
of forskolin-mediated corticosterone synthesis is dependent
upon the activation of ERK1/2 and is correlated with phos-
phorylation of SF-1 and increased StAR gene transcription
[15]. Accordingly, inhibition of ERK1/2, by either PD98059
or U0126, decreases StAR expression and steroid produc-
tion without aﬀecting P450scc enzyme activity. Increasing
evidence demonstrates that ACTH and angiotensin II (Ang
II) can elevate phosphorylation of p44/p42 MAPKs and
result in increases in StAR expression and steroid synthesis
that involve PKC signaling and Ras/Raf-1 kinase [80–
83]. The induction of orexins A and B (neuropeptide
hormones) mediated StAR expression and steroid synthesis
is mediated by a number of MAPK cascades including
EKR1/2 activation, where the latter requires multiple G-
protein signaling pathways in human H295R adrenocortical
cells [55, 84]. It has been demonstrated that while proo-
piomelanocortin (POMC) fragments, 1-28-POMC and 1-
48-POMC, modulate cellular proliferation, they decrease
adrenal steroidogenesis by activating ERK1/2 signaling [85].
Chronic administration of ACTH induces the phosphory-
lation of ERK1/2 that occurs in parallel with adrenal corti-
costerone synthesis in adult rats [82]. In both H295R and
primary cultures of human adrenocortical cells, treatment
with adipokines up-regulates the ERK1/2 cascade and results
in increases in StAR expression and aldosterone synthesis,
processes that do not require cAMP/PKA signaling [86, 87].
Taken together, it seems clear that the ERK1/2 signaling
cascade plays diverse roles in regulating StAR expression
and steroidogenesis. These roles could be a result of the
existence of multiple signal transduction pathways that
display diﬀerences in receptor-eﬀector coupling between
tissues and species.
2.2. p38 MAPK Signaling and Its Role in Steroidogenesis. The
p38 MAPK signaling cascade is thought to participate in
the response of cells to stress. Four members of the p38
MAPKfamilyhavebeenclonedandnamedp38α(MAPK14),
p38β (p38-2), p38γ (ERK6 or SAPK3), and p38δ (SAPK4)
and share approximately 60% homology in their amino
acid sequences [10, 88–91]. Also, several alternatively spliced
isoforms of p38 MAPK include Mxi2 (identical to p38α)
and Exip. P38 MAPKs contain a Thr-Gly-Tyr activation loop6 Journal of Signal Transduction
sequence (TGY). They are activated by dual phosphory-
lations on threonine and tyrosine residues in response to
numerous stimuli, including cytokines, hormones, GPCRs,
heat shock, and other stresses and play important roles in
controlling many cellular functions [42, 53, 92, 93]. P38α
is expressed in most cells; however, expression of other
isoforms is tissue speciﬁc. Cellular distribution, activation,
and substrate speciﬁcity of p38 MAPKs result in diverse
biological functions. Once activated, p38 MAPKs either
transmit the signals via a three-tier cascade or phosphory-
late other regulatory molecules such as PLA2, heat shock
proteins, and transcriptions factors (c-Jun, ATF-2, CREB,
CHOP, NF-kB, and others) [8, 42, 92, 94]. Substrates of p38
MAPK include MAPK-activated protein kinases (MKs), that
i s ,M K 2 ,M K 3 ,a n dM K 5( r e v i e w e di n[ 1, 53, 95, 96]). There
are also several distinct kinases at the MAP3K level of the
p38 MAPK cascade, including MLK2, MLK3, TPL2, dual
leucine zipper-bearing kinase, ASK1, MAP three kinase 1,
and TAK1 [91, 97, 98]. Studies have reported the existence
of p38 signaling crosstalk with other MAPK cascades. For
instance, the p38 MAPK pathway causes rapid inactivation
of the ERK1/2 cascade mediated by PP2A [99]. The p38
MAPK pathway is involved in tissue homeostasis and several
pathologies ranging from inﬂammation and the immune
response to cancer and neurodegenerative diseases [93, 100,
101].
The p38 MAPK signaling cascade has been implicated
in regulating steroidogenesis. It has been demonstrated that
IL-1α activates p38 MAPK and that this event is associated
withStARexpressionand testosteronesynthesis inimmature
rat Leydig cells [102, 103]. The involvement of p38 MAPK
in steroidogenesis is further assessed by observations in
which inhibition of its activity, either by SB203580 or
PD169316, results in the coordinate suppression of StAR
and steroid levels. IL-1α is also capable of phosphorylating
CREB and Fos/Jun through the activation of a p38 substrate
which is a RSK family member (RSK-B kinase, also called
MSK2), suggesting that this process may play a role in the
diﬀerentiation of immature into adult Leydig cells [102]. In
addition, it is worth noting that IL-1α also activates ERK1/2
and inhibition of the latter by U0126 augments expression
and phosphorylation of the StAR protein but decreases
androgen synthesis by dissipating the mitochondrial elec-
trochemical potential [63]. These ﬁndings suggest that a
number of MAPKsignaling eventsdiﬀerentiallyinﬂuenceIL-
1α-mediated steroidogenesis in mouse Leydig cells.
Gonadotropins have been shown to activate both p38
and ERK1/2 MAPKs and result in varying eﬀects on StAR
expression and steroidogenesis in ovarian granulosa cells
[16,17,51,104].Studieshavedemonstratedthatinterference
of p38 (by SB203580) and ERK1/2 (by PD98059 and U0126)
activity is associated with increases in LH/hCG/FSH medi-
ated StAR expression and progesterone synthesis [16, 51,
104].Inaddition,inhibitionofp38decreasesbothP450arom
andestradiolsynthesis, andtheseeventsaretightlycorrelated
with liver receptor homolog-1 and DAX-1 expression [104],
demonstrating that p38 targets these transcription factors
in regulating steroidogenesis. Heat shock protein HSP-27
is identiﬁed as a downstream phosphorylation target of
FSH-andforskolin-mediated p38MAPKactivation[105].In
granulosa cell-oocyte cocultures, both bone morphogenetic
protein-2 (BMP-2) and BMP-4 exert diﬀerential eﬀects on
FSH mediated regulation of steroidogenesis through the
activation of p38 MAPK [106]. Indeed, both BMP-2 and -
4 increase FSH-mediated P450arom mRNA expression and
estradiol production but decrease StAR and progesterone
levels.
In primary cultures of rat adrenal glomerulosa cells,
Ang II activates the p38 and ERK1/2 signaling pathways
and results in increases in StAR expression, steroidogenic
enzymes, and steroid synthesis [83, 107]. Concurrently, Ang
II inhibits protein synthesis by enhancing p27kip1 expression
(a protein known to block the cell cycle in the G1 phase).
The eﬀects of Ang II can be reversed through inhibition
of p38 activity by SB203580, suggesting that Ang II plays
an important role in adrenal physiology. Accumulating
evidenceindicates thatactivation of thep38 MAPK signaling
cascade is linked to the aging-induced, oxidative stress-
mediated suppression of steroidogenesis in adrenal cells
[108–110]. Alternatively, inhibitors of p38 MAPKs (by
either SB203580 or SB202190) and antioxidants (reactive
oxygen species (ROS) scavengers MnTMPyP and N-acetyl
cysteine) have beenshown to restore corticosteronesynthesis
in cells from aged rats. These ﬁndings indicate that the
stress-mediated inhibition of steroid biosynthesis involves
the activation of the p38 MAPK pathway in the adrenals
during the course of aging [110]. Also, intense phospho-p38
MAPKimmunoreactivity has beendetectedinhumanbrains
of postmortem patients aﬄicted with Alzheimer’s disease
[111, 112], indicating that p38 could be involved in the
pathogenesis of this disease.
2.3. JNK/SAPK Signaling and Its Role in Steroidogenesis.
JNK/SAPKs are also considered as stress-activated MAPKs;
however, they are diﬀerent from p38 MAPKs [1, 113,
114]. Isolation and subsequent characterization of cDNAs
encoding these enzymes revealed three genes encoding
proteins with 10 or more alternatively spliced forms. Three
main isoforms, that is, JNK1/SAPKγ (46kDa), JNK2/SAPKα
(54kDa), and JNK3/SAPKβ (52kDa), are approximately
85% identical in their core catalytic domains [115, 116].
Whereas JNK1/2 MAPKs are ubiquitously expressed, JNK3
is primarily localized to neuronal tissues, testis and car-
diac myocytes. JNK/SAPKs are activated by cytokines, UV
irradiation, growth-factor deprivation, agents that interfere
with DNA and protein synthesis, as well as other stressors.
Similar to other MAP kinases, the activity of JNK/SAPKs is
dependent upon phosphorylation on tyrosine and threonine
residues, which are separated by a proline to generate the
TPY motif in the activation loop. The resulting signals
are then transmitted to three-tier cascades either directly
or through MAP4Ks [117, 118]. Several kinases are phos-
phorylated in these cascades [1, 41]. However, two MEK
family members, MKK4 (SEK1, MEK4, JNKK1, and SKK1)
and MKK7 (MEK7, JNKK2, and SKK4), are predominantly
involved in the JNK/SAPK cascade for signal integration
[117–119].Journal of Signal Transduction 7
Several lines of evidence demonstrate the involvement
of the JNK/SAPK signaling cascade in steroidogenesis.
For example, tumor necrosis factor-α (TNFα)a c t i v a t e s
JNK/SAPK; however, the latter is associated with decreases
in basal and cAMP-induced steroidogenesis by reducing
Cyp17 gene expression in MA-10 cells [120]. TNFα also
decreases the phosphorylation of ERK1/2 while simultane-
ously increasing the abundance of cJun as well as increasing
AP-1 binding activity, suggesting the involvement of a num-
berofMAPKsinTNFαsignaling.Therefore,theactivationof
JNK/SAPK and ERK1/2 MAPKs appears to play a mutually
antagonistic role in TNFα-mediated steroidogenesis. In rat
R2C Leydig tumor cells, bisphenol A (BPA), an endocrine
disruptor, is capable of activating JNK/SAPK and results
in an elevation in aromatase activity and an attenuation
of testosterone synthesis by targeting both CREB and Akt
[121]. Increasing evidence demonstrates that steroidogenesis
decreases in aging, a time when the levels of reactive oxygen
species (ROS) increase. As a consequence, a number of
ROS,such assuperoxideanion (O2
−)and hydrogenperoxide
(H2O2), have been involved in the repression of testicular
StAR expression and steroid synthesis [122–124]. In K28
mouse Leydig cells, the inhibition of ROS-mediated StAR,
P450c17 mRNA, and steroid levels is mediated, at least
in part, through the activation of JNK/SAPK MAPKs and
subsequent upregulation of c-Jun [124]. These events cause
a repression in the trans-activation potential of Nur77 on
steroidogenic enzyme genes and result in decreases in StAR
expression and steroidogenesis.
In human granulosa cells, leptin activates a number of
MAPKs including the JNK/SAPK signaling pathway where
it decreases cAMP-induced StAR protein expression and
progesterone synthesis [75]. Likewise, BMPs can induce
phosphorylation of several MAPK cascades, exhibit varying
actions on steroidogenesis, and play important roles in
ovarian follicular growth and maturation [73, 125, 126].
Also, an oocyte derived factor, FGF-8, has been shown to
interact with BMPs, activate the JNK/SAPK and ERK1/2
signaling cascades and subsequently regulate FSH-induced
steroidogenesis in a rat granulosa cell-oocyte coculture
system [73]. Altogether, the JNK/SAPK signaling cascade
is fundamentally connected with stress-related responses
and the activation of JNK/SAPK decreases the steroidogenic
response in a number of steroidogenic tissues.
2.4. ERK5/BMK1 Signaling and Its Role in Steroidogene-
sis. The ERK5/BMK1 is the largest known MAP kinase
(∼110kDa) family member. The signaling pathway leading
to ERK5 activation is poorly understood in comparison with
other MAPKs as a consequence of conﬂicting ﬁndings in the
literature [127–130]. Importantly, the C-terminus of ERK5
contains 10 consensus MAP kinase phosphorylation sites
which can be autophosphorylated [131]. ERK5 is ubiqui-
tously expressed and its activity is regulated by a variety
of proliferative (growth factors, phorbol ester, serum, and
lysophosphatidic acid) and cell-stressing (H2O2, sorbitol,
and UV irradiation) agents [132, 133]. The mechanism
of upstream activation of the ERK5 cascade has not been
fully deﬁned. This mechanism may include the action of
adaptor proteins (e.g., LAD), protein tyrosine kinases, and
WNK1 [134–136]. These components have been shown to
induce a number of kinases at the level of MAP3K, including
MEKK2/3, TPL2, and MLTK [135, 137–139]. These kinases
then phosphorylate MEK5 (an upstream component of
ERK5) on serine and threonine residues [127]. MEK5 then
activates ERK5 on threonine and tyrosine residues in the
loop sequence motif (TEY) identical to ERK1 and ERK2.
However, ERK5 cannot be phosphorylated by MEK1/2, and
MEK5 does not phosphorylate ERK1/2. Another substrate
of ERK5 is the serum and glucocorticoid-inducible kinase,
w h i c hm a ys e r v ea saM A P K A P Ko ft h i sc a s c a d e ,a l l o w i n g
for the possible involvement of a ﬁve-tier cascade [140].
ERK5 can aﬀect a number of cellular activities (e.g., cellular
proliferation, diﬀerentiation, and motility) by phosphory-
lating many transcription factors, including MADs box, c-
Myc, c-Fos, myocyte enhancer factors 2A and C, and SAP1a
[133, 141–143].
Relatively little is known regarding the role of ERK5 in
steroidogenesis. Recently, it has been reported that orexins A
and B activate ERK5 and concomitantly increase expression
of the StAR protein and steroidogenic enzyme genes in
H295R cells [55, 84]. These agents can also augment cortisol
secretion in primary cultures of adrenal cells. The eﬀects of
orexins on ERK5 phosphorylation have been demonstrated
to be similar to those of Ang II and are mediated by multiple
G-protein signaling pathways. However, orexins simultane-
ously activate the ERK1/2 and p38 MAPK signaling cascades
[55], indicating that the regulation of orexin-mediated StAR
expression and steroidogenesis involves several MAPKs in
adrenal cells. Information that the activation of the ERK5
signaling pathwayin gonadalcellsislinkedtosteroidogenesis
is currently lacking.
3.Other MAP Kinases
ERK3, ERK4, ERK7, NLK, MOK, and others are considered
as atypical MAPKs (Table 1). Regulation, structure, and
substrate speciﬁcity of these MAPKs have been described in
a recent review [5]. The roles of these atypical MAPKs in
steroidogenesis remain to be elucidated.
4.Conclusions
The MAPK signaling cascades are the major components
of pathways controlling a wide variety of cellular processes,
including embryogenesis, gene expression, acute responses
to hormones, cell survival, and apoptosis and are of critical
importance in the transduction of extracellular signals in
cells. Noteworthy, the MAPK cascade has been implicated in
the pathogenesis of a number of human disorders, including
Alzheimer’s disease, Parkinson’s disease, and many cancers.
Indeed, the multiple eﬀects of MAPKs could be a result of
the involvement of a wide variety of substrates that include
protein kinases and phosphatases, transcription factors,
cytoskeletal elements, and other signal-regulated molecules.
The studies summarized here have emphasized the roles8 Journal of Signal Transduction
of ERK1/2, p38 MAPK, JNK/SAPK, and ERK5 MAPKs in
the regulation of StAR expression and steroidogenesis in
diﬀerent steroidogenic tissues. The StAR protein plays an
indispensable role in the production of steroid hormones
required for bodily homeostasis and normal reproductive
development and function. Based on the results available
at this time, it is obvious that the MAPK signaling cas-
cades play diverse roles in controlling StAR expression
and steroid biosynthesis in tissue-, stimulus-, and pathway-
speciﬁc manners. These processes appear to be dependent
on receptor-eﬀector coupling, signaling crosstalk, and/or
other factor(s) involved in steroidogenesis. Moreover, under
speciﬁc circumstances, the regulation of MAPK-dependent
StAR expression and steroidogenesis involves more than
one MAPK signaling, and as a consequence diﬀerent, and
even opposing, eﬀects of MAPKs can be seen in diﬀerent
steroidogenic cells. Additionally, diﬀerent cells express dis-
tinct sets of transcription factors, and this diversity may
account for the cell-type-dependent speciﬁcity of MAPK
action. Given the physiological and pathological roles of the
MAPKsignalingpathways,elucidationoftissue-anddisease-
speciﬁc eﬀects of each of the MAPK signaling cascades
together with their downstream eﬀectors requires better
understanding. An abundance of molecular tools including
high throughput genomic and proteomic technologies will
undoubtedly provide valuable insights into these regulatory
mechanisms.
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